PetLife Pharmaceuticals Announces the Addition of Dr. Simon Wood PhD as the Company’s new Scientific Officer with plans to expand its Current Portfolio of Veterinarian Drugs and Nutraceuticals
19. Oktober 2016 15:15 ET
|
PetLife Pharmaceuticals, Inc.
Hancock, MD, Oct. 19, 2016 (GLOBE NEWSWIRE) -- PetLife Pharmaceuticals, Inc. (OTC QB: PTLF) (the "Company"), a developer of a new generation of high potency veterinary cancer medications and...
PetLife Pharmaceuticals is Pleased to Announce the Completion of the New Company Website
17. Oktober 2016 08:00 ET
|
PetLife Pharmaceuticals, Inc.
Hancock, MD, Oct. 17, 2016 (GLOBE NEWSWIRE) -- PetLife Pharmaceuticals, Inc. (OTC QB: PTLF) (the "Company"), a developer of a new generation of high potency veterinary cancer medications and...
PetLife Pharmaceuticals Expands Cell Line Study with InnoVision in Preparation for FDA/CVM Registration Submission
13. Oktober 2016 08:00 ET
|
PetLife Pharmaceuticals, Inc.
Hancock, MD, Oct. 13, 2016 (GLOBE NEWSWIRE) -- PetLife Pharmaceuticals, Inc. (OTC QB: PTLF) (the "Company"), a developer of a new generation of high potency veterinary cancer medications and...
PetLife Pharmaceuticals is Pleased to Showcase its New “Vitalzul™ Information Video” along with a Corporate Update
10. Oktober 2016 08:00 ET
|
PetLife Pharmaceuticals, Inc.
Hancock, MD, Oct. 10, 2016 (GLOBE NEWSWIRE) -- PetLife Pharmaceuticals, Inc. (OTC QB: PTLF) (the "Company"), a developer of a new generation of high potency veterinary cancer medications and...
PetLife Pharmaceuticals Explores Product Expansion with Strategic Partner(s); Successfully Presents at Two Financial Conferences in September
28. September 2016 10:30 ET
|
PetLife Pharmaceuticals, Inc.
Hancock, MD , Sept. 28, 2016 (GLOBE NEWSWIRE) -- PetLife Pharmaceuticals, Inc. (OTC QB: PTLFD) (the "Company"), the developer of Vitalzul™, a new generation of high potency veterinary cancer...
PetLife Pharmaceuticals Continues Execution of its Vitalzul TM Business Plan with start of Proof of Concept studies; Provides Updates
14. September 2016 09:10 ET
|
PetLife Pharmaceuticals, Inc.
Hancock, MD, Sept. 14, 2016 (GLOBE NEWSWIRE) -- Hancock, MD - PetLife Pharmaceuticals, Inc. (OTC QB: PTLFD) (the "Company"), a developer of Vitalzul™, a new generation of high potency veterinary...
PetLife Pharmaceuticals Announces pre-INAD (Investigational New Animal Drug) Cell Lines Study of Vitalzul™ has Begun
07. September 2016 11:00 ET
|
PetLife Pharmaceuticals, Inc.
Hancock, MD, Sept. 07, 2016 (GLOBE NEWSWIRE) -- PetLife Pharmaceuticals, Inc. (OTC QB: PTLF) (the "Company"), a developer of a new generation of high potency veterinary cancer medications and...
PetLife Pharmaceuticals Sees Vitalzul™ as a Major Component in the Treatment of Cancer in Pets; Releases Vitalzul™ Information and Testimonial Video
01. September 2016 09:00 ET
|
PetLife Pharmaceuticals, Inc.
Hancock, MD, Sept. 01, 2016 (GLOBE NEWSWIRE) -- PetLife Pharmaceuticals, Inc. (OTC QB: PTLF) (the "Company"), a developer of a new generation of high potency veterinary cancer medications and...
PetLife Pharmaceuticals Hires InnoVision Therapeutics in Preparation of Vitalzul™ FDA Submission
25. August 2016 08:43 ET
|
PetLife Pharmaceuticals, Inc.
HANCOCK, Md., Aug. 25, 2016 (GLOBE NEWSWIRE) -- PetLife Pharmaceuticals, Inc. (OTCQB:PTLF) (the "Company"), a developer of a new generation of high potency veterinary cancer medications and...
PetLife Pharmaceuticals Announces Investor Analysts Research Report
23. August 2016 14:35 ET
|
PetLife Pharmaceuticals, Inc.
Hancock, MD, Aug. 23, 2016 (GLOBE NEWSWIRE) -- PetLife Pharmaceuticals, Inc. (OTCQB: PTLF) (the "Company"), a developer of a new generation of high potency veterinary cancer medications and...